Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailAntiplatelet Activity of Clopidogrel in Coronary Artery Bypass Graft Surgery Patients
David, Jean-Louis ULg; Limet, Raymond ULg

in Thrombosis and Haemostasis (1999), 82(5), 1417-21

Clopidogrel is a recently introduced platelet ADP receptor antagonist, belonging to the thienopyridine derivatives, like its analogue ticlopidine. Its potential advantage is to be safer than ticlopidine ... [more ▼]

Clopidogrel is a recently introduced platelet ADP receptor antagonist, belonging to the thienopyridine derivatives, like its analogue ticlopidine. Its potential advantage is to be safer than ticlopidine. At 75 mg/od clopidogrel significantly inhibits platelet aggregation in ambulatory patients with symptomatic atherosclerotic disease and it prevents the recurrence of ischemic events more efficiently than aspirin. Its adequate dose in more acute situations remained to be determined. Therefore, sixty two patients with coronary artery disease were randomly assigned in four groups treated, within 24 h after coronary artery bypass graft, by clopidogrel 50 mg/od, 75 mg/od or 100 mg/od or by ticlopidine 250 mg/bid which was considered as the reference. The tolerance of clopidogrel was fairly good during the whole period of the study. Bleeding time and ex-vivo platelet aggregation induced by ADP 2 microM and 5 microM were performed at day -1, +9 and +28 after surgery. Like ticlopidine, the three dose levels of clopidogrel significantly inhibited ex-vivo platelet activity and prolonged the bleeding time at day 28. However, unlike ticlopidine, the inhibitory effects of clopidogrel were not significant at day 9, especially with 75 mg/od, a dose which was found to significantly protect patients in a chronic situation. Hence, although the clinical outcome for patients included in this limited study was the same in the four groups, these results suggest that the dose regime of clopidogrel should be more extensively investigated during the early period following coronary artery bypass graft, facing an overproduction of young and hyperreactive platelets. By analogy, the dose regime should be also investigated in other situations with an acute risk of arterial thrombotic occlusion. [less ▲]

Detailed reference viewed: 18 (0 ULg)
Full Text
Peer Reviewed
See detailAntiplatelet therapy in the perioperative period.
Engelen, S.; Sinaeve, P.; Van Damme, Hendrik ULg et al

in Acta Anaesthesiologica Belgica (2010), 61

antiplatelet drugs are the cornerstone treatment in the secondary prevention of arterial thrombosis. Until recently, their intake was interrupted in the perioperative period because of fear for bleeding ... [more ▼]

antiplatelet drugs are the cornerstone treatment in the secondary prevention of arterial thrombosis. Until recently, their intake was interrupted in the perioperative period because of fear for bleeding, but new insights have challenged this old habit. in patients at high risk for atherothrombotic events who need to undergo surgery or an invasive procedure, the risk for bleeding complications because of a treatment with low-dose acetylsalicylic acid (lD aSa) needs to be balanced against the risk of atherothrombotic events after treatment discontinuation. for patients at high risk of atherothrombotic complications recent guidelines do no longer advocate to interrupt lD aSa routinely. However, the likelihood of bleeding versus atherothrombotic complications should be considered on a case-by-case basis. when continued perioperatively, the bleeding risk associated with thienopyridines (ticlopidine, clopidogrel and prasugrel) is higher than that of lD aSa. it is recommended to stop their intake 1 week before the surgical intervention, except in patients with (recent) coronary stenting [less ▲]

Detailed reference viewed: 16 (1 ULg)
See detailAntipodean Dialogue in the Novels of David Malouf
Delrez, Marc ULg

Conference (1988)

Detailed reference viewed: 15 (0 ULg)
See detailAntipodean Dialogue: Randolph Stow and David Malouf
Delrez, Marc ULg

in Davis, Geoffrey V.; Maes-Jelinek, Hena (Eds.) Crisis and Creativity in the New Literatures in English (1990)

Detailed reference viewed: 36 (1 ULg)
Full Text
Peer Reviewed
See detailAntiproliferative and genotoxic effects of Mikania glomerata (Asteraceae)
Dalla Nora, G; Pastori, T; Laughinghouse IV, Haywood ULg et al

in Biocell : Official Journal of the Sociedades Latinoamericanas de Microscopia Electronica ... Et. Al (2010), 34(3), 95-101

Detailed reference viewed: 25 (0 ULg)
Full Text
Peer Reviewed
See detailAntiproliferative effect of the arboreal and medicinal species Luehea divaricata on the Allium cepa cell cycle
Frescura, VDS; Laughinghouse IV, Haywood ULg; Tedesco, SB

in Caryologia : Giornale di Citologia, Citosistematica, e Citogenetica (2012), 65(1), 27-33

Detailed reference viewed: 32 (2 ULg)
Full Text
Peer Reviewed
See detailAntiproton and Antilambda Annihilations on Several Nucleons
Cugnon, Joseph ULg; Vandermeulen, Jacques

in Physical Review. C : Nuclear Physics (1989), 39

Detailed reference viewed: 7 (0 ULg)
Full Text
Peer Reviewed
See detailAntiproton Annihilation at Rest on Light Nuclei : Rescattering, Strange Particle Yield and B = 1 Annihilation
Cugnon, Joseph ULg; Deneye, Pierre; Vandermeulen, Jacques

in Nuclear Physics A (1990), 517

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailAntiproton Annihilation Inside Nuclei
Cugnon, Joseph ULg; Cahay, M.; jasselette, Pierre et al

in Physics Letters B (1982), 115

Detailed reference viewed: 9 (0 ULg)
Full Text
Peer Reviewed
See detailAntiproton Annihilation on Nuclei
Cugnon, Joseph ULg

in Bunce, G.M. (Ed.) Proceedings of the Third International Conference on the Intersections Between Nuclei and Particles (1988)

Detailed reference viewed: 8 (1 ULg)
Full Text
Peer Reviewed
See detailAntiproton-Nucleus Annihilation
Cugnon, Joseph ULg

in Richard, Jean-Marc; Aslanidès, E.; Boccara, N. (Eds.) The Elementary Structure of Matter (1988)

Detailed reference viewed: 10 (0 ULg)
Full Text
Peer Reviewed
See detailAntiproton-Nucleus Interaction
Cugnon, Joseph ULg; Vandermeulen, Jacques

in Annales de Physique Fr. (1989), 14

Detailed reference viewed: 5 (0 ULg)
Full Text
Peer Reviewed
See detailAntiprotozoal and cytotoxic triterpenoid saponins from the roots of Cephalaria gigantea
Tabatadze, Nino; Elias, Riad; Delmas, F. et al

Poster (2006, July)

Detailed reference viewed: 43 (0 ULg)
See detailL'antipsychiatre et la plume
Tilkin, Françoise ULg

in Revue belge de philologie et d'histoire (1982), 60(4), 1083-1084

Detailed reference viewed: 10 (0 ULg)
Full Text
Peer Reviewed
See detailL'antipsychologisme de Brentano
Boccaccini, Federico ULg

in Gyemant, Maria (Ed.) Psychologie et psychologisme (2015)

Detailed reference viewed: 53 (8 ULg)
Full Text
Peer Reviewed
See detailAntipsychotics and Neuropeptides: The Atypical Profile of Ci-943 and Its Relationship to Neurotensin
Liégeois, Jean-François ULg; Bonaventure, P.; Delarge, J. et al

in Neuroscience & Biobehavioral Reviews (1995), 19(4, Winter), 519-31

CI-943 is a new drug candidate with antipsychotic-like activity in a variety of behavioural tests in rodents and primates, but without any affinity for brain dopamine receptors. CI-943 does not cause ... [more ▼]

CI-943 is a new drug candidate with antipsychotic-like activity in a variety of behavioural tests in rodents and primates, but without any affinity for brain dopamine receptors. CI-943 does not cause dystonia in monkeys, a predictive symptom of extrapyramidal side effects (EPS). Its mechanism of action remains unclear. Neurotensin (NT) concentration in nucleus accumbens and caudate is increased by CI-943; this may be associated with its antipsychotic effect. Indeed various observations suggest that the clinical action of antipsychotic drugs may at least be partially mediated by some neuropeptides. Various actions of neurotensin are reviewed. The hypothesis on the role of neurotensin represents a new strategy in the development of pharmacological tools for the treatment of schizophrenia. [less ▲]

Detailed reference viewed: 13 (1 ULg)
Full Text
Peer Reviewed
See detailLes antipsychotiques atypiques dans la dépression résistante
PITCHOT, William ULg; Constant E; Floris M et al

in Acta Psychiatrica Belgica (2012)

Detailed reference viewed: 21 (1 ULg)
See detailL'antiquité classique comme source d'inspiration dans l'oeuvre de Karel Tchapek
Mouton, Charles ULg

in Slavica Gandensia (1993), 20

Detailed reference viewed: 69 (2 ULg)
See detailL’Antiquité et le Moyen Âge
Jadoulle, Jean-Louis ULg; Hasquin, Hervé

Book (2008)

Detailed reference viewed: 18 (3 ULg)